Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 fusion |
Therapy | Gemcitabine + Pemigatinib |
Indication/Tumor Type | cholangiocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 fusion | cholangiocarcinoma | sensitive | Gemcitabine + Pemigatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of Gemzar (gemcitabine) and Pemazyre (pemigatinib) synergistically inhibited viability of a cholangiocarcinoma cell line harboring an FGFR2 fusion in culture, and led to inhibition of tumor growth in a cell line xenograft model (PMID: 38801887). | 38801887 |
PubMed Id | Reference Title | Details |
---|---|---|
(38801887) | The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. | Full reference... |